Attorneys Analyze FDA’s Case Against Utah Medical, Impact On Industry
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Deputy Chief Counsel Eric Blumberg says the agency will continue to prosecute firms with weak quality controls, even if there are no reports of safety problems.
You may also be interested in...
J&J Sues Boston Scientific, Abbott For $5.5 Bil For Breach Of Contract
After losing bidding war for Guidant, J&J charges winning firms with using leaked information.
State Drug Advertising Laws Foreshadow Future Device Regulation
Some state lawmakers contend that industry's voluntary code of ethics is insufficient, according to Kyphon's chief compliance officer.
FDA Official Distinguishes Scientific Exchange From Off-Label Promotion
Agency compliance head Tim Ulatowski says he's not concerned about the scientific exchange of information on products.